0001145443-12-001418.txt : 20121221 0001145443-12-001418.hdr.sgml : 20121221 20121221170536 ACCESSION NUMBER: 0001145443-12-001418 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20121217 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20121221 DATE AS OF CHANGE: 20121221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYCOR MEDICAL INC CENTRAL INDEX KEY: 0001424768 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203369218 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34932 FILM NUMBER: 121282620 BUSINESS ADDRESS: STREET 1: 6401 CONGRESS AVE STREET 2: SUITE 140 CITY: BOCA RATON, STATE: FL ZIP: 33487 BUSINESS PHONE: 562.558.2000 MAIL ADDRESS: STREET 1: 6401 CONGRESS AVE STREET 2: SUITE 140 CITY: BOCA RATON, STATE: FL ZIP: 33487 8-K 1 d30031.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 17, 2012

 

Vycor Medical, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

333-149782

 

20-3369218

(State or Other Jurisdiction

 

(Commission File Number) 

 

(IRS Employer Identification No.)  

of Incorporation)

 

 

 

 


6401 Congress Ave., Suite 140

 

 

Boca Raton, FL.

 

33487

(Address of Principal Executive Offices) 

 

(Zip Code)

 

Registrant's telephone number, including area code: (561) 558-2000

 

(Former name or former address, if changed since last report)

                                                       

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)

 

 

 




Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 17, 2012, Richard P. Denness notified the Company that he was resigning his position as Chief Executive Officer of the Company effective December 31, 2012.  Mr. Denness’ decision to resign was for strictly personal reasons and did not arise or result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. Mr. Denness has agreed to remain as a consultant with the Company for a transition period.  At the same time, Mr. Denness advised the Company that he is also resigning from his position on the Company’s board of directors with immediate effect.  


Mr. Denness's duties will be absorbed by the remaining executive team of the President David Cantor, Executive Vice-President Peter Zachariou and the Chairman and Chief Financial Officer Adrian Liddell.


On December 21, 2012, the Company issued a press release related to Mr. Denness’ resignation, a copy of which is attached to this Report as Exhibit 99.1.  




Item 9.01


Financial Statements and Exhibits


(d)           Exhibits


99.1


Press Release dated December 21, 2012





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Dated: December 21, 2012

 

Vycor Medical, Inc.


/s/ David Cantor

By:  David Marc Cantor

Title:  President





 EX-99.1 2 d30031_ex99-1.htm EX-99.1 Converted by EDGARwiz

EXHIBIT 99.1


Vycor Medical, Inc. Announces Management Change


BOCA RATON, FL (December 21, 2012) – Vycor Medical, Inc. (“Vycor” or “Company”) (OTCBB: VYCO) announced today that Richard Denness will resign as the Company’s CEO effective December 31, 2012, and as a member of the Board of Directors effective immediately.  Mr. Denness will remain as a consultant to the Company during a transition period.  The Board will seek to appoint a successor CEO in due course.


Mr. Denness’ decision to resign was for strictly for personal reasons and did not arise or result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.


Vycor has established a solid strategy for its Vycor Medical and NovaVision divisions. Mr. Denness' duties will be absorbed by the remaining executive team of the President, David Cantor, Executive Vice-President Peter Zachariou and the Chairman and CFO, Adrian Liddell.


About Vycor Medical, Inc.

Vycor Medical, Inc. is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective.  The company’s flagship patent pending ViewSite™ Surgical Access Systems represent an exciting new minimally invasive access and retraction system that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor’s innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, and CE Marking and HPB licensing in Canada. 


Vycor Medical’s subsidiary, NovaVision, Inc., researches, develops and provides science-driven vision-based neurostimulation therapy and other medical technologies that help to improve sight in patients with neurological vision impairments.  The company’s proprietary Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury or other acquired brain injury, and has been 510(K) cleared to be marketed in the US by the FDA. VRT can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. NovaVision, through its subsidiary Sight Science, also provides Neuro-Eye Therapy (NeET), aimed at increasing visual sensitivity deep within the field defect. NovaVision also provides a fully portable and ADA-compliant Head Mounted Perimeter (HMPTM) which aids in the detection and measurement of visual field deficits

 



For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com or www.novavision.com.


Safe Harbor Statement


Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


Contact for Vycor Medical, Inc.:


The Del Mar Consulting Group, Inc.

Robert B. Prag, President

858-794-9500

bprag@delmarconsulting.com


or


Alex Partners, LLC

Scott Wilfong, President

425-242-0891

scott@alexpartnersllc.com


###